Persulfide Composition for CD4+ T Cell Modulation in Inflammatory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments do not effectively address the role of active sulfur molecules in T cell immune responses and their application in clinical practice for inflammatory bowel diseases and type 2 airway inflammations.
Innovation Solution
A pharmaceutical composition containing persulfides, such as glutathione trisulfide, is administered to regulate CD4+ T cell activation and proliferation, thereby treating or preventing inflammatory bowel diseases and type 2 airway inflammations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory treatments are used, then inflammation symptoms are suppressed, but they do not effectively address the role of active sulfur molecules in T cell immune responses
Solution Approach 1:
The patent introduces a novel parameter - active sulfur molecules (specifically persulfides like GSSSG) - to modulate T cell immune responses. This changes the biochemical parameter space by introducing sulfur-based compounds that specifically target CD4+ T cell activation and proliferation pathways, thereby addressing the effectiveness gap in conventional treatments while maintaining broad adaptability to various inflammatory conditions
2Productivity
If active sulfur molecules are administered to suppress CD4+ T cell proliferation, then inflammatory bowel diseases and type 2 airway inflammations are treated, but the mechanism is not yet fully understood
Solution Approach 1:
The patent establishes preliminary findings that active sulfur molecules suppress CD4+ T cell proliferation and differentiation into pathogenic subsets before fully elucidating the molecular mechanism. This preliminary action demonstrates therapeutic efficacy in inflammatory bowel diseases and type 2 airway inflammations, providing a foundation for further mechanistic studies while already delivering clinical benefits
Data Source
Figure 1
Figure 2A~2E
Figure 3A~3C
AI summary
The present invention relates to a pharmaceutical composition for preventing or treating an inflammatory bowel disease, a type 2 airway inflammation or the like, containing an active sulfur molecule as an active ingredient. Specifically, the present invention relates to a pharmaceutical composition for treating or preventing an inflammatory bowel disease or a type 2 airway inflammation, containing a persulfide represented by Formula (1) described below or a pharmaceutically acceptable salt or solvate thereof: R1S(S)n R2 (1), where R1 and R2 are independently selected from L-cysteine, homocysteine, and glutathione (GSH), and represent moieties other than a thiol group; and n is an integer of 2 or more.